TY - JOUR
T1 - Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) para tratamento biológico de transtornos depressivos unipolares, 1a parte
T2 - Tratamento agudo e de continuação do transtorno depressivo maior
AU - Bauer, Michael
AU - Whybrow, Peter C.
AU - Angst, Jules
AU - Versiani, Marcio
AU - Möller, Hans Jürgen
AU - Allain, Hervé
AU - Anderson, Ian
AU - Ayuso-Gutierrez, José L.
AU - Baldwin, David
AU - Bech, Per
AU - Benkert, Otto
AU - Berk, Michael
AU - Bitter, Istvan
AU - Bourgeois, Marc L.
AU - Burrows, Graham
AU - Cassano, Giovanni
AU - Cetkovich-Bakmans, Marcelo
AU - Cookson, John C.
AU - Costa, Delcir Da
AU - Gheroghe, Mihai D.
AU - Heinze, Gerardo
AU - Higuchi, Teruhiko
AU - Hirschfeld, Robert M.
AU - Höschl, Cyril
AU - Holsboer-Trachsler, Edith
AU - Kasper, Siegfried
AU - Katona, Cornelius
AU - Keller, Martin B.
AU - Kulhara, Parmanand
AU - Kupfer, David J.
AU - Lecrubier, Yves
AU - Leonard, Brian
AU - Licht, Rasmus W.
AU - Lingjaerde, Odd
AU - Lublin, Henrik
AU - Mendlewicz, Julien
AU - Mitchell, Philip
AU - Paykel, Eugene S.
AU - Puzynski, Stanislaw
AU - Rush, A. John
AU - Rybakowski, Janusz K.
AU - Schweitzer, Isaac
AU - Unützer, Jürgen
AU - Verstergaard, Per
AU - Vieta, Eduard
AU - Yamada, Kazuo
AU - Wiltfang, Jens
PY - 2009
Y1 - 2009
N2 - These practice guidelines for the biological treatment of unipolar depressive disorders were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal for developing these guidelines was to systematically review all available evidence pertaining to the treatment of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating patients with these conditions. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for depressive disorders, as well as from meta-analyses and reviews on the efficacy of antidepressant medications and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and was then categorized into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of unipolar depressive disorders, as well as the management of the acute and continuation-phase treatment. These guidelines are primarily concerned with the biological treatment (including antidepressants, other psychopharmacological and hormonal medications, electroconvulsive therapy, light therapy, adjunctive and novel therapeutic strategies) of young adults and also, albeit to a lesser extent, children, adolescents and older adults.
AB - These practice guidelines for the biological treatment of unipolar depressive disorders were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal for developing these guidelines was to systematically review all available evidence pertaining to the treatment of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating patients with these conditions. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for depressive disorders, as well as from meta-analyses and reviews on the efficacy of antidepressant medications and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and was then categorized into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of unipolar depressive disorders, as well as the management of the acute and continuation-phase treatment. These guidelines are primarily concerned with the biological treatment (including antidepressants, other psychopharmacological and hormonal medications, electroconvulsive therapy, light therapy, adjunctive and novel therapeutic strategies) of young adults and also, albeit to a lesser extent, children, adolescents and older adults.
KW - Acute treatment
KW - Antidepressants
KW - Biological treatment
KW - Continuation treatment
KW - Evidence-based guidelines
KW - Major depressive disorder
KW - Pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=77949670413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949670413&partnerID=8YFLogxK
U2 - 10.1590/S0101-60832009000800001
DO - 10.1590/S0101-60832009000800001
M3 - Review article
AN - SCOPUS:77949670413
SN - 0101-6083
VL - 36
SP - 17
EP - 57
JO - Revista de Psiquiatria Clinica
JF - Revista de Psiquiatria Clinica
IS - SUPPL. 2
ER -